Erratum to: Cutaneous Complications of Targeted Melanoma Therapy

In the original version of this article, which published in Current Treatment Options in Oncology, Volume 17, Issue 11, November 2016, the drug “cobimetinib” was erroneously referred to as “cometinib” throughout the text.

Author information

Authors and Affiliations

Department of Dermatology, Cutaneous Oncology, Stanford University Medical Center and Cancer Institute, 780 Welch Road, CJ220F, Palo Alto, CA, 94304-5779, USA
Emily de Golian, Bernice Y. Kwong, Susan M. Swetter & Silvina B. Pugliese
Dermatology Service, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA
Susan M. Swetter

Authors

Emily de Golian
View author publications
You can also search for this author in PubMed Google Scholar
Bernice Y. Kwong
View author publications
You can also search for this author in PubMed Google Scholar
Susan M. Swetter
View author publications
You can also search for this author in PubMed Google Scholar
Silvina B. Pugliese
View author publications
You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Silvina B. Pugliese.

Additional information

The online version of the original article can be found at http://dx.doi.org/10.1007/s11864-016-0434-0.

Rights and permissions

Reprints and permissions

About this article

Cite this article

de Golian, E., Kwong, B.Y., Swetter, S.M. et al. Erratum to: Cutaneous Complications of Targeted Melanoma Therapy. Curr. Treat. Options in Oncol. 17, 63 (2016). https://doi.org/10.1007/s11864-016-0440-2

Download citation

Published: 05 November 2016
DOI: https://doi.org/10.1007/s11864-016-0440-2

Use our pre-submission checklist

Avoid common mistakes on your manuscript.